MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ncrna.2025.08.002

Медицинская библиотека · Non-coding RNA research · 2025

Identification of plasma tRNA-derived small RNA i-tRF-15:31-Lys-CTT-1 as a biomarker for diagnosis and prognosis of pulmonary arterial hypertension.

Chen Yusi, Zhu Tengteng, Li Fang, Tan Yingjie, Wang Tianyu, Luo Xiaoqin, Luo Jun, Tang Yi, Peng Jianqiang, Li Jiang

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

tRNA-derived small RNAs (tsRNAs) are emerging as noninvasive biomarkers of cellular damage. However, their role in pulmonary arterial hypertension (PAH) remains unclear.

METHODS

Plasma i-tRF-15:31-Lys-CTT-1 levels were quantified in a discovery cohort (n = 141 PAH patients; n = 50 controls) and a verification cohort (n = 254 PAH patients; n = 70 controls). Diagnostic performance was assessed using receiver operating characteristic analysis, and survival outcomes were evaluated with Kaplan-Meier curves and multivariable Cox regression models.

RESULTS

In discovery cohort, the median age was 41 years (IQR 27-54), with 65.9 % female and a median REVEAL 2.0 score of 7 (IQR 6-8). In verification cohort, the median age was 36 years (IQR 31-52), with 63.4 % female and a median REVEAL 2.0 score of 6 (IQR 4-7). i-tRF-15:31-Lys-CTT-1 showed the greatest fold change among tsRNAs in idiopathic PAH (P < 0.0001). Levels of i-tRF-15:31-Lys-CTT-1 were significantly lower in the high-risk REVEAL group (P < 0.0001). The area under the curve (AUC) of i-tRF-15:31-Lys-CTT-1 for idiopathic PAH diagnosis was 0.90 in discovery cohort and 0.81 in verification cohort. Kaplan-Meier analysis revealed that lower i-tRF-15:31-Lys-CTT-1 levels correlated with poorer prognosis (P < 0.0001). After adjusting for age, sex, and BMI, patients in the highest quartile had a significantly lower incidence of clinical events compared to those in the lowest quartile (HR = 0.08; 95 % CI 0.032-0.18; P < 0.001). Incorporating i-tRF-15:31-Lys-CTT-1 into the REVEAL 2.0 model improved predictive accuracy (AUC from 0.67 to 0.75, P < 0.0001).

CONCLUSIONS

i-tRF-15:31-Lys-CTT-1 levels are decreased in PAH, correlate with disease severity, and are promising to improve clinical diagnosis and risk stratification.

Для цитирования: Chen Yusi, Zhu Tengteng, Li Fang, Tan Yingjie, Wang Tianyu, Luo Xiaoqin, Luo Jun, Tang Yi, Peng Jianqiang, Li Jiang. Identification of plasma tRNA-derived small RNA i-tRF-15:31-Lys-CTT-1 as a biomarker for diagnosis and prognosis of pulmonary arterial hypertension.. Non-coding RNA research. 2025. DOI: 10.1016/j.ncrna.2025.08.002.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.